

## References

I-162

1. Chiorean EG, Sweeney C, Youssoufian H, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFR $\alpha$ ) monoclonal antibody, in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2014;595–604.
2. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. *Lancet* 2016; 388: 488–97.
3. Van der Graaf, WTA. Olaratumab in soft-tissue sarcomas. *Lancet*. 2016;442-444.
4. NCCN Drugs & Biologics Compendium™. Olaratumab. 2019. National Comprehensive Cancer Network (NCCN).
5. MICROMEDEX@SOLUTIONS Compendia. 2019. Olaratumab
6. Wagner A, Kindler H, Gelderblom H, et al. A Phase II Study of a Human Anti-PDGFR $\alpha$  Monoclonal Antibody (Olaratumab, IMC-3G3) in Previously Treated Patients with Metastatic Gastrointestinal Stromal Tumors. *Ann Oncol*. 2017.;28(3):541-546.
7. Zuluago-Sanchez S, Hess L, Wolowacz S, et al. Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States. *Sarcoma*. 2018;6703963:1-14.
8. Clinical Pharmacology Compendia. 2019 Tampa FL: Gold Standard, Inc. Olaratumab.
9. Lartruvo [package insert]. Indianapolis, IN: Eli Lilly and Company; October 2018.